{"schema_version":"secwatch.filing_event.v1","accession":"0001023024-25-000107","form_type":"8-K","ticker":"ANIP","cik":"0001023024","company_name":"ANI PHARMACEUTICALS INC","filed_at":"2025-11-07T23:59:59+00:00","discovered_at":"2026-05-14T18:02:38.570511+00:00","generated_at":"2026-05-16T22:54:59.248807+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"confidence":"high","headline":"ANI Pharmaceuticals reports record Q3 2025 revenue and raises full-year guidance","bullets":["Record quarterly net revenues of $227.8 million, up 53.6% year-over-year.","Purified Cortrophin Gel net revenues rose 93.8% to $101.9 million.","Adjusted non-GAAP EBITDA of $59.6 million, up 69.8%.","Raised 2025 total net revenue guidance to $854M-$873M and adjusted EPS to $7.37-$7.64.","GAAP diluted EPS of $1.13 vs. net loss of $1.27 per share in prior year period."],"urls":{"canonical":"https://secwatch.observer/filing/0001023024-25-000107","json":"https://secwatch.observer/filing/0001023024-25-000107.json","markdown":"https://secwatch.observer/filing/0001023024-25-000107.md","text":"https://secwatch.observer/filing/0001023024-25-000107.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1023024/000102302425000107/0001023024-25-000107-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1023024/000102302425000107/ani-20251107.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud","generated_at":"2026-05-16T22:54:59.248807+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}